.[J] Chinese Pharmaceutical Journal, 2011,V46(16): 1290-1292
��
[1]
FDA. Guidance for Industry�� Bioequivalence Guidance [EB/OL]. FDA��2006�� [2011-4-20]. http��//www. fda. gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052363. pdf.[2] XUE J��ZOU W B��CUI XW��et al. Principles for quality evaluation of marketed metformin hydrochloride tablets [J]. Chin J New Drugs ���й���ҩ��־����2011��20 ��3���� 274-279. [3] GAO S H. Preparation of crystal form A of cimetidine [J]. Chin J Pharm ���й�ҽҩ��ҵ��־����1991��22 ��10���� 473. [4] SFDA. Drug Administration Law of the People��s Republic of China��Chapter 5 [EB/OL]. SFDA��2001�� [2011-6-23]. http��//jk. xihele. com/yaox/ysgl/ysfg/200704/20070411110700. html.[5] SFDA. Good Clinical Practice [EB/OL]. SFDA��2003�� [2011-4-20]. http��//www. sda. gov. cn/WS01/CL0053/24473. html.[6] FDA��CDER. Approved Drug Products with Therapeutic Equivalence Evaluations ��Orange Book�� 29th ed [EB/OL]. FDA��2009 iv-xxiii [2011-4-20]. http��//www. fda. gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436. pdf.[7] SFDA. Guidance for Human Bioavailability and Bioequivalence Studies for Chemical Pharmaceutical Preparations [EB/OL]. SFDA��2005�� [2011-4-20]. http��//www. sda. gov. cn/gsz05106/08. pdf.[8] HUANG Q��WEI C M. Preliminary discussion on evaluation of bioequivalence for highly variable drugs and drug products [J]. Chin J Clin Pharmacol Therapeut ���й��ٴ�ҩ��ѧ������ѧ���� 2007��12 ��8���� 841-844. [9] FDA. Guidance for Industry�� Food-Effect Bioavailability and Fed Bioequivalence Studies [EB/OL]. FDA��2002�� [2011-4-20]. http��//www. fda. gov/downloads/RegulatoryInformation/Guidances/UCM126833. pdf.[10] SFDA. Disqualified essential drugs of 28 batches[J]. Chin Health ���й���������2010��10�� 8. [11] GU G D��FANG K H. Analysis and suggestion on the disqualified situation of drug spotcheck in Yangzhou city in 2003 [J]. Jiangsu Pharm Clin Res ������ҩѧ���ٴ��о�����2004��3�� 58-60. [12] CHEMBURKAR S R��BAUER J��DEMING K��et al. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development [J]. Org Process Res Dev��2000��4 ��5���� 413-417. [13] SFDA. Guidance for Normalization Process of Establishing the Quality Standard for Chemical Pharmaceutical Preparations [EB/OL]. SFDA��2005�� [2011-4-20]. http��//www. sda. gov. cn/gsz05106/16. pdf.[14] SFDA. Guidance for the Study of the Chemicals of the Obtained National Standards [EB/OL]. SFDA��2006�� [2011-4-20]. http��//www. sda. gov. cn/WS01/CL0844/10613. html.
2011, Vol. 46 